Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Availability of naloxone in Canadian pharmacies:a population-based survey.

Cressman AM, Mazereeuw G, Guan Q, Jia W, Gomes T, Juurlink DN.

CMAJ Open. 2017 Nov 8;5(4):E779-E784. doi: 10.9778/cmajo.20170123.

2.

The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study.

Choremis B, Campbell T, Tadrous M, Martins D, Antoniou T, Gomes T.

PLoS One. 2019 Oct 18;14(10):e0223589. doi: 10.1371/journal.pone.0223589. eCollection 2019.

3.

Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.

Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM.

JAMA Netw Open. 2019 Jun 5;2(6):e195388. doi: 10.1001/jamanetworkopen.2019.5388.

4.

Assessment of naloxone availability in Georgia community pharmacies.

Stone RH, Hur S, Young HN.

J Am Pharm Assoc (2003). 2019 Dec 19. pii: S1544-3191(19)30509-6. doi: 10.1016/j.japh.2019.11.003. [Epub ahead of print]

PMID:
31866387
5.

Availability of Naloxone in Pharmacies and Knowledge of Pharmacy Staff Regarding Dispensing Naloxone to Younger Adolescents.

Jimenez DE, Singer MR, Adesman A.

J Adolesc Health. 2019 Nov;65(5):698-701. doi: 10.1016/j.jadohealth.2019.07.009. Epub 2019 Sep 17.

PMID:
31540779
6.

Pharmacist dispensed naloxone: Knowledge, availability, participation and cost in selected California counties.

Darracq MA, Lee J, Wilson T, Lasoff D, Armenian P.

Int J Drug Policy. 2019 Sep;71:113-117. doi: 10.1016/j.drugpo.2019.06.001. Epub 2019 Jul 10.

PMID:
31301549
7.

Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies.

Graves RL, Andreyeva E, Perrone J, Shofer FS, Merchant RM, Meisel ZF.

J Addict Med. 2019 Jul/Aug;13(4):272-278. doi: 10.1097/ADM.0000000000000492.

PMID:
30585876
8.

Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.

Melaragni F, Levy C, Pedrazzi J, Andersen M.

J Am Pharm Assoc (2003). 2019 Jul - Aug;59(4):550-554.e2. doi: 10.1016/j.japh.2019.04.012. Epub 2019 May 17.

PMID:
31109812
9.

Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.

Sisson ML, McMahan KB, Chichester KR, Galbraith JW, Cropsey KL.

Int J Drug Policy. 2019 Dec;74:229-235. doi: 10.1016/j.drugpo.2019.09.021. Epub 2019 Nov 5.

PMID:
31698165
10.

Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.

Lozo KW, Nelson LS, Ramdin C, Calello DP.

J Med Toxicol. 2019 Apr;15(2):108-111. doi: 10.1007/s13181-019-00700-7. Epub 2019 Feb 25.

PMID:
30805884
11.

Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.

Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR.

J Am Pharm Assoc (2003). 2019 Oct 25. pii: S1544-3191(19)30423-6. doi: 10.1016/j.japh.2019.09.007. [Epub ahead of print]

PMID:
31669417
12.

Access to naloxone at community pharmacies under the Massachusetts statewide standing order.

Wu C, Brown T, Moreno JL.

J Am Pharm Assoc (2003). 2019 Dec 13. pii: S1544-3191(19)30515-1. doi: 10.1016/j.japh.2019.11.009. [Epub ahead of print]

PMID:
31843374
13.

Pharmacy study of natural health product adverse reactions (SONAR): a cross-sectional study using active surveillance in community pharmacies to detect adverse events associated with natural health products and assess causality.

Necyk C, Tsuyuki RT, Boon H, Foster BC, Legatt D, Cembrowski G, Murty M, Barnes J, Charrois TL, Arnason JT, Ware MA, Rosychuk RJ, Vohra S.

BMJ Open. 2014 Mar 28;4(3):e003431. doi: 10.1136/bmjopen-2013-003431.

14.

The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.

Burrell A, Ethun L, Fawcett JA, Rickard-Aasen S, Williams K, Kearney SM, Pringle JL.

J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S73-S77.e1. doi: 10.1016/j.japh.2016.11.006. Epub 2017 Jan 19.

PMID:
28109629
15.

Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Bailey AM, Wermeling DP.

Ann Pharmacother. 2014 May;48(5):601-6. doi: 10.1177/1060028014523730. Epub 2014 Feb 12.

16.

Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians.

Kurian S, Baloy B, Baird J, Burstein D, Xuan Z, Bratberg J, Tapper A, Walley A, Green TC.

J Am Pharm Assoc (2003). 2019 Nov - Dec;59(6):824-831. doi: 10.1016/j.japh.2019.08.009. Epub 2019 Sep 30.

PMID:
31582224
17.

First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.

Uosukainen H, Bell JS, Laitinen K, Tacke U, Ilomäki J, Turunen JH.

Int J Drug Policy. 2013 Sep;24(5):492-7. doi: 10.1016/j.drugpo.2013.02.004. Epub 2013 Apr 6.

PMID:
23567099
18.

The role of policy in community pharmacies' response to injection-drug use: results of a nationwide Canadian survey.

Myers T, Cockerill R, Millson M, Rankin J, Worthington C.

AIDS Public Policy J. 1996 Summer;11(2):78-88.

PMID:
10915241
19.
20.

Naloxone.

Jordan MR, Morrisonponce D.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 19.

Supplemental Content

Support Center